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Brief Definitive Report
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Summary
 
Hemofiltrate C-C chemokine (HCC)-1 is a recently cloned C-C chemokine that is structur-
ally similar to macrophage inflammatory protein (MIP)-1
 
a
 
. Unlike most chemokines, it is con-
stitutively secreted by tissues and is present at high concentrations in normal human plasma.
Also atypical for chemokines, HCC-1 is reported not to be chemotactic for leukocytes. In this
paper, we have investigated the chemokine receptor usage and downstream signaling pathways
of HCC-1. Cross-desensitization experiments using THP-1 cells suggested that HCC-1 and
MIP-1
 
a
 
 activated the same receptor. Experiments using a panel of cloned chemokine receptors
revealed that HCC-1 specifically activated C-C chemokine receptor (CCR)1, but not closely
related receptors, including CCR5. HCC-1 competed with MIP-1
 
a
 
 for binding to CCR1-
transfected cells, but with a markedly reduced affinity (IC
 
50
 
 
 
5 
 
93 nM versus 1.3 nM for MIP-
1
 
a
 
). Similarly, HCC-1 was less potent than MIP-1
 
a
 
 in inducing inhibition of adenylyl cyclase
in CCR1-transfected cells. HCC-1 induced chemotaxis of freshly isolated human monocytes,
THP-1 cells, and CCR1-transfected cells, and the optimal concentration for cell migration
 
(100 nM) was 
 
z
 
100-fold lower than that of MIP-1
 
a
 
 (1 nM). These data demonstrate that
HCC-1 is a chemoattractant and identify CCR1 as a functional HCC-1 receptor on human
monocytes.
Key words: hemofiltrate C-C chemokine • C-C chemokine receptor 1 • chemokine • 
chemotaxis • macrophage inflammatory protein 1
 
a
C
 
hemokines are small (8–10 kD), secreted basic pep-
tides that are involved in the directed migration and
activation of leukocytes (for review see references 1, 2).
The majority of chemokines can be divided into two
groups, based on the arrangement of the first two of four
conserved cysteines. The 
 
a
 
-, or “C-X-C”, branch includes
IL-8, GRO (
 
a
 
, 
 
b
 
, 
 
g
 
), neutrophil-activating peptide
(NAP)-2, and platelet factor 4, and is characterized by the
presence of a single amino acid between the first two cys-
teines. In the 
 
b
 
-, or “C-C” branch, the first two cysteines
are adjacent. Members of the 
 
b
 
-branch include the mono-
cyte chemoattractant protein (MCP)-1, RANTES (regu-
lated on activation, normal T cell expressed and secreted),
macrophage inflammatory protein (MIP)-1
 
a
 
, MIP-1
 
b
 
, and
eotaxin. In general, C-X-C chemokines are chemotactic
for neutrophils, whereas the C-C chemokines are chemo-
tactic for monocytes and lymphocytes. In addition to their
conserved structural motifs, the chemokines share certain
functional properties, including a lack of constitutive secre-
tion by cells, extremely low to nondetectable circulating
levels in the plasma of healthy persons, and the ability to
induce chemotaxis of leukocytes.
Hemofiltrate C-C chemokine (HCC)-1 is a recently de-
scribed monocyte chemoattractant, originally isolated from
the hemofiltrate of patients with chronic renal failure (3).
Determination of the amino acid sequence of HCC-1 re-
vealed four cysteine residues in positions characteristic of
the C-C chemokine family, and comparison with the se-
quences of other chemokines revealed that HCC-1 was
most homologous to MIP-1
 
a
 
. However, several functional
properties of HCC-1 were atypical of chemokines. Unlike
other chemokines, HCC-1 was expressed constitutively in
a number of tissues and was present at high concentrations
in normal human plasma. In addition, HCC-1 was re-
ported not to be chemotactic for leukocytes (3). We have
examined the chemokine receptor usage of HCC-1 and its
functional properties on both primary leukocytes and cell
lines transfected with cloned chemokine receptors. Here,
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we report that the endogenous receptor for HCC-1 is the
C-C chemokine receptor 1 (CCR1) and that binding of
HCC-1 leads to the generation of classical second messen-
gers and a robust chemotactic response.
 
Materials and Methods
 
Reagents.
 
Chemokines were obtained from R&D Systems
(Minneapolis, MN) and PeproTech, Inc. (Rocky Hill, NJ).
HCC-1 was synthesized at Pfizer as described below. Lipo-
fectamine, RPMI 1640, and MEM with Earle’s balanced salt
were from GIBCO BRL (Gaithersburg, MD). M1 antibody was
obtained from Kodak (Eastman Kodak Co., Rochester, NY).
FCS was from Hyclone Laboratories (Logan, UT). [
 
g
 
-
 
32
 
P]ATP
and [
 
3
 
H]adenine were purchased from DuPont-NEN (Boston,
MA). All other reagents were obtained from Sigma Chemical Co.
(St. Louis, MO), unless otherwise noted.
 
Cells.
 
PBMCs were prepared from healthy adult donors. Af-
ter the addition of heparin (20 U/ml; Elkin-Sinn, Cherry Hill,
NJ), venous blood was subjected to centrifugation on Ficoll-
Hypaque (1,000 
 
g
 
, 45 min, 25
 
8
 
C). The buffy coat of PBMCs at
the interface was harvested, and contaminating erythrocytes were
removed by hypotonic lysis. The PBMCs were washed and resus-
pended in cell culture medium. Monocytes were prepared as pre-
viously described (4). THP-1 cells were obtained from the Amer-
ican Type Culture Collection (Clone TIB-202, ATTC 30-2001,
Rockville, MD) and grown in RPMI 1640 supplemented with
10% FCS, 1 mM sodium pyruvate, 2 mM glutamine, 10 mM
Hepes, 100 U/ml penicillin/streptomycin, and 0.1 mM nones-
sential amino acids (BioWhittaker, Walkersville, MD). The 300-
19 lymphocyte-like cell line (5) was a gift from Dr. Greg LaRosa
(Leuko-Site, Inc., Cambridge, MA).
 
Transfected Cells.
 
HEK-293 cells stably expressing CCR1,
CCR2, CCR5, and CXCR1 were prepared as previously de-
scribed (6). 300-19 cells stably expressing CCR4 and CCR3 were
prepared as previously described for CCR2 (7) and CCR5 (8).
HEK-293 cells transiently expressing human CCR6, CCR7, and
CCR8 were prepared as previously described (9). The cDNAs for
CCR6, CCR7, and CCR8 were obtained using oligonucleotides
corresponding to published DNA sequences (10–13) and standard
PCR protocols. All PCR products were completely sequenced.
 
Assays.
 
Calcium fluorometry and adenylyl cyclase measure-
ments were performed as previously described (7). HCC-1 was
labeled with the Bolton-Hunter reagent (diiodide; DuPont-
NEN) as previously described (9). Unconjugated iodide was sep-
arated from labeled protein by elution through a PD-10 column
(Pharmacia Biotech, Piscataway, NJ) equilibrated with PBS and
BSA (1% wt/vol). Competition binding was performed as de-
scribed (9), and IC
 
50
 
 values were determined using the program
“Prism” (GraphPad, Inc., San Diego, CA).
 
Chemotaxis.
 
Human monocyte chemotaxis studies were per-
formed using a 48-well Boyden chamber (Neuro Probe, Inc.,
Cabin John, MD). PBMCs (2 
 
3 
 
10
 
5
 
) were added to the upper
chamber, and the indicated concentrations of the agonists to the
lower chamber. The upper and lower chambers were separated
by a 5-
 
m
 
m PVP-coated filter. Chambers were incubated for 90
min at 37
 
8
 
C in a humidified incubator in the presence of 5%
CO
 
2
 
. The filter was removed and the upper surface was scraped
to remove nonadherent cells and stained with DiffQuik (Fisher
Scientific Co., Pittsburgh, PA). The number of migrating cells in
six randomly chosen high-power fields was counted. Chemotaxis
studies of THP-1 cells were performed using a 96-well neuro-
probe apparatus (Neuro Probe, Inc.). Agonists were placed in the
bottom wells, and THP-1 cells (800,000 cells/well) were added
to the upper wells. After a 3-h incubation (37
 
8
 
C, 5% CO
 
2
 
, 95%
humidity), the upper chambers were washed free of cells, the top
of the filter was scraped, and EDTA was added. After 20 min, the
plate and filter were centrifuged, and the number of cells that mi-
grated was determined by colorimetry using fluorescein diacetate.
Chemotaxis studies of 300-19 cells stably expressing CCR1 were
performed using a transwell apparatus, as previously described (7).
 
Chemical Synthesis of HCC-1.
 
Automated Fmoc-based solid-
phase peptide syntheses were performed on solid-phase peptide
synthesizer (model 431 A; software version Synthassist 2.0; PE
Applied Biosystems, Foster City, CA) retrofitted with deprotec-
tion monitoring. HBTU (benzotriazoleyl tetramethyluronium
hexafluophosphate) activation and single amino acid coupling cy-
cles were used, except following sluggish deprotection steps, in
which case the following residue was double coupled. Syntheses
were started using 0.25 mmol preloaded Fmoc amino acid
(Wang) resin, 50% of the resin cake was removed midway
through the synthesis, and the synthesis was completed. The final
synthesis resin was cleaved and deprotected by treatment with a
solution of 83% TFA (trifluoroacetic acid), 5% phenol, 5% water,
and 2.5% ethandithiol for 1 h, 23
 
8
 
C. The mixture was filtered,
the TFA filtrate was diluted into 50 ml of diethylether, and the
precipitated crude peptide salt was collected by centrifugation.
The peptide was purified by preparative reverse-phase HPLC (20 
 
3
 
250 mm Waters C18 column; Waters Corp., Milford, MA) using
a water/acetonitrile (0.1% TFA) gradient. Fractions were assayed
by analytical HPLC (4.5 
 
3 
 
250 mm Vydac C18 column; West-
ern Analytical, Murrieta, CA), appropriate fractions were pooled
(
 
.
 
85% purity), and the resulting solution was adjusted with re-
dox additives (final concentrations: 0.5 mM cysteine, 0.5 mM
cystine, 10 mM methionine, 75 mM Hepes, pH 8.0, 0.05–0.5
mg/ml peptide). The reaction was essentially complete after 15 h
at 4
 
8
 
C, as indicated by a shift to shorter retention time on analyt-
ical HPLC. The oxidized product was purified as above to 
 
.
 
98%
purity. Concentration was estimated by UV absorbance at 280
nm and confirmed by amino acid analysis (Michigan Protein
Structure Facility, Ann Arbor, MI). The product was aliquoted,
lyophilized, and stored at 
 
2
 
80
 
8
 
C. Electrospray mass (PE-Sciex
API100) of folded HCC-1 1–74 
 
5 
 
8673.3 daltons (calculated:
8673.8 daltons), 4–74 
 
5 
 
8342.8 daltons (calculated: 8343.4 dal-
tons), 6–74 
 
5 
 
8126.7 daltons (calculated: 8127.2 daltons).
 
Results
 
The cDNA for HCC-1 encodes a predicted protein of
93 amino acids (Fig. 1). We synthesized three variants of
HCC-1, based upon the method of Neilsen et al. (14) for
predicting signal sequence cleavage points. Thus, threonine
20, glutamic acid 23, and serine 25 were all considered po-
tential NH
 
2
 
 termini of the mature protein.
To identify its receptor, we tested HCC-1’s ability to ac-
tivate cloned C-C or C-X-C chemokine receptors ex-
Figure 1. Amino acid sequence of HCC-1. The sequence of the full-
length protein is shown on the top line. Three NH2-terminally truncated
variants of HCC-1 (20–93, 23–93, and 25–93), based on alternative sites
for cleavage of the putative signal sequence, are indicated.
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pressed in stably transfected cells. As seen in Fig. 2, HCC-1
(20–93) induced a robust and prompt mobilization of intra-
cellular calcium in cells expressing CCR1, but not in cells
expressing CCR2, CCR3, CCR4, CCR5, or CXCR1. In
control experiments, the CCR2-transfected cells gave a ro-
bust response to MCP-1, the CCR3 cells to eotaxin, the
CCR4 cells to thymus and activation–regulated chemokine
(TARC), the CCR5 cells to MIP-1
 
a
 
, and the CXCR1
cells to IL-8 (data not shown). In addition, although HEK-
293 cells transiently transfected with CCR6, CCR7, or
CCR8 failed to respond to HCC-1, they signaled well to
liver and activation–regulated chemokine (LARC), sec-
ondary lymphoid tissue chemokine (SLC), and I-309, re-
spectively (data not shown). These data provided the first
evidence that CCR1 is a functional receptor for HCC-1.
Ligation of CCR1 by MIP-1
 
a
 
 or RANTES causes acti-
vation of G
 
a
 
i, inhibition of adenylyl cyclase, and a fall in
cAMP levels (6). Similarly, addition of HCC-1 to CCR1-
transfected cells caused a dose-dependent decrease in cAMP
(Fig. 3). Comparison of the three NH
 
2
 
-terminally trun-
cated variants of HCC-1 revealed that the rank order of
potency was inversely correlated with the length of the
protein. Thus, the shortest version of HCC-1 (25–93) was
the most potent (IC
 
50
 
 
 
5 
 
8 nM), and the longest version of
HCC-1 (20–93) was the least potent (IC
 
50
 
 
 
5 
 
49 nM).
However, even the most potent form of HCC-1 was at
least 10-fold less active than either MIP-1
 
a
 
 or RANTES in
inducing activation of CCR1.
Competition binding studies confirmed that HCC-1
bound to CCR1 (Fig. 4), but with lower affinity than
MIP-1
 
a
 
 (IC
 
50
 
 for HCC-1 
 
5 
 
93 nM, as compared with 1.3
nM for MIP-1
 
a
 
). These data are consistent with the rela-
tive potencies determined in the cyclase assay above.
Further evidence that CCR1 is a functional receptor for
HCC-1 was obtained using chemotaxis assays. As seen in
Fig. 5 
 
A
 
, HCC-1 induced robust migration of a lympho-
cyte cell line (300-19) stably transfected with CCR1. The
maximal chemotactic response to HCC-1 was achieved at
100 nM, a concentration 
 
z
 
1,000-fold higher than that of
MIP-1
 
a
 
. However, when present at their optimal concen-
trations HCC-1 and MIP-1
 
a
 
 attracted similar numbers of
cells. Consistent with the results of the cyclase assays, the
shorter variant of HCC-1 was a more efficient chemoat-
tractant than the longer version (Fig. 5 
 
B
 
).
Evidence that CCR1 is the endogenous HCC-1 recep-
tor on human mononuclear cells was sought using cell lines
and freshly isolated human monocytes. As seen in Fig. 6,
HCC-1 was a chemoattractant for both purified monocytes
(Fig. 6 
 
A
 
) and THP-1 cells (Fig. 6 
 
B
 
). Optimal migration
required 
 
z
 
100–500 times more HCC-1 than MIP-1
 
a
 
,
which is consistent with the results obtained using CCR1-
transfected 300-19 cells (Fig. 5).
Figure 2. HCC-1 induces cal-
cium mobilization in cells ex-
pressing CCR1. Each of the in-
dicated chemokine receptors,
except CCR3 and CCR4, was
stably expressed in HEK-293
cells. CCR3 and CCR4 were ex-
pressed in 300-19 cells. All cells
were loaded with Indo-1 AM and
then challenged with HCC-1
(100 nM). Intracellular calcium
levels were measured as described
in Materials and Methods. Data
shown are typical of at least three
independent experiments.
Figure 3. HCC-1 induces inhibition of adenylyl cyclase in cells ex-
pressing CCR1. HEK-293 cells stably expressing CCR1 were labeled
with [3H]adenine and incubated with 10 mM forskolin in the presence of
increasing concentrations of RANTES, MIP-1a, or each of the three
variants of HCC-1. [3H]cAMP levels were determined as described in
Materials and Methods. The IC50 values were as follows: RANTES, 0.15
nM; MIP-1a, 0.8 nM; HCC-1 (25–93), 8 nM; HCC-1 (23–93), 14 nM;
HCC-1 (20–93), 49 nM. All data points were determined in duplicate.
Shown is one of three similar experiments.
Figure 4. Competition binding of HCC-1 to CCR1. Radiolabeled
MIP-1a (1.5 nM) was added to HEK-293 cells stably expressing CCR1
in the presence of the indicated concentrations of unlabeled MIP-1a or
HCC-1. Binding to untransfected cells was negligible (m). The IC50 for
HCC-1, determined as described in Materials and Methods, was 1.3 nM
for MIP-1a and 93 nM for HCC-1.
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Further evidence that CCR1 is the endogenous monocyte
receptor for HCC-1 was obtained in cross-desensitization ex-
periments. MIP-1
 
a
 
 effectively desensitized monocytes to
HCC-1, but not to MCP-1 (Fig. 7 
 
A
 
), and very similar re-
sults were seen using RANTES (Fig. 7 
 
B
 
). Conversely,
HCC-1 desensitized monocytes to MIP-1
 
a
 
 (Fig. 7 
 
C). In
contrast, incubation of monocytes with MIP-1b, which acti-
vates CCR5 but not CCR1, failed to induce a measurable
intracellular calcium flux, but the subsequent addition of
HCC-1 did (Fig. 7 D). Direct evidence of cross-desensitiza-
tion was obtained in assays using HEK-293 cells expressing
transfected CCR1. As shown in Fig. 7 E, MIP-1a desensi-
tized the CCR1-expressing cells to HCC-1, and, conversely,
HCC-1 desensitized the cells to MIP-1a (Fig. 7 F).
Discussion
The major finding in this study is that CCR1, a well-
characterized receptor for the C-C chemokines MIP-1a
(15), RANTES (15), MCP-3 (16), and MCP-2 (17), is also
a functional receptor for HCC-1. Several lines of evidence
support this conclusion. First, HCC-1 induced a rapid mo-
bilization of intracellular calcium, as well as inhibition of
adenylyl cyclase, in CCR1-transfected HEK-293 cells. Sec-
ond, this response was specific for CCR1 in that HCC-1
failed to induce signaling in cells transfected with CCR2,
CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, or CXCR1.
The failure to induce activation of CCR5 is particularly
significant because MIP-1a, the chemokine to which
HCC-1 is most homologous, is a potent ligand for CCR5.
Third, the dose–response studies revealed that HCC-1 was
z100-fold less potent than MIP-1a in activating CCR1,
in close agreement with the relative potency reported for
inducing proliferation of CD341 myeloid progenitor cells
(3). Fourth, HCC-1 competed with MIP-1a for binding
to CCR1. Consistent with the signaling data, the affinity of
HCC-1 for CCR1 was z100-fold less than MIP-1a. Fifth,
HCC-1 induced chemotaxis of CCR1-transfected 300-19
cells with a classical biphasic dose-dependency. The opti-
mal HCC-1 concentration for chemotaxis was z100 nM,
as compared with 0.1–1.0 nM for MIP-1a. Finally, evi-
dence that CCR1 is the endogenous monocyte receptor
for HCC-1 was obtained in cross-desensitization studies.
Pretreatment with either MIP-1a or RANTES, but not
MIP-1b, completely blocked the response of monocytes to
HCC-1, and the converse was also true when HCC-1 was
added at high concentrations. Since HCC-1 does not acti-
vate CCR5, these results strongly suggest competition for
binding to CCR1. Taken together, these data indicate that
HCC-1 is a functional ligand for CCR1.
Figure 5. HCC-1 induces
CCR1-dependent chemotaxis.
(A) 300-19 cells stably expressing
CCR1 migrated towards the in-
dicated concentrations of HCC-1
and MIP-1a. (B) Comparison
of the long (20–93) and short
(25–93) variants of HCC-1 in
inducing chemotaxis. Error bars
represent standard deviation.
Shown is one of at least three
similar experiments.
Figure 6. HCC-1 induces
monocyte chemotaxis. (A)
Freshly isolated primary human
monocytes migrated towards the
indicated concentrations of MIP-
1a or HCC-1. (B) THP-1 cells.
Chemotaxis for each cell type
was performed as described in
Materials and Methods. Error
bars denote standard deviations.
Shown is one of at least three
similar experiments.
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The cDNA for HCC-1 encodes a 93–amino acid pro-
tein, with a putative 19-residue leader sequence (3). Analy-
sis of the NH2-terminal domain by the method of Neilsen
et al. (14) revealed at least three other possible sites for
cleavage of the signal peptide, yielding proteins of 74, 71,
and 69 amino acids. In patients with renal failure, the pre-
dominate form of HCC-1 appears to be the 74–amino acid
variant (3). Interestingly, the shorter forms of HCC-1 were
significantly more potent on a molar basis than the 74–
amino acid form. Earlier studies reported that HCC-1 in-
duced an elevation of intracellular calcium, but failed to
induce chemotaxis of human monocytes (3). This was a
surprising result, since chemotaxis is the prototypic func-
tion of this family of cytokines. The failure of HCC-1 to
induce chemotaxis would thus have provided intriguing
evidence for distinct and agonist-specific signal transduc-
tion pathways downstream of a chemokine receptor (i.e.,
induction of chemotaxis in response to activation of CCR1
by MIP-1a or RANTES, but not by HCC-1). Our results
demonstrate that HCC-1 does indeed induce chemotaxis
via activation of CCR1, albeit at a higher concentration
than MIP-1a. HCC-1’s chemotactic effect was observed
with CCR1-transfected cells, THP-1 cells, and freshly iso-
lated primary human monocytes.
The finding that HCC-1 is a ligand for CCR1 and has
chemotactic activity raises the question of the physiological
significance of the chronically high levels of HCC-1 in the
plasma. Since the dissociation constant for binding to CCR1
and the plasma concentration of HCC-1 are approximately
equal (z100 nM), about half of the CCR1 molecules at
the cell surface would be expected to be occupied by
HCC-1. The leukocyte might therefore be unable to re-
spond to small changes in HCC-1 levels but could retain
the ability to respond to other CCR1 agonists, such as
MIP-1a and RANTES, since these chemokines bind to
CCR1 with a much higher affinity than HCC-1. This sce-
nario is very much in keeping with the model of combina-
torial control of leukocyte chemotaxis recently proposed
by Foxman et al. (18). In this case, however, multiple ago-
nists of different affinity for the same receptor (i.e., CCR1),
rather than sequential activation of different chemokine re-
ceptors, may be responsible for the navigation of mono-
cytes through complex chemoattractant gradients. MIP-1g,
a murine chemokine with homology to HCC-1, is se-
creted constitutively in vivo, is present in the plasma of
healthy mice at a concentration of z90 nM, and competes
with MIP-1a for the same receptor on murine neutrophils
(19). MIP-1g may thus be the murine equivalent of HCC-1.
Finally, these studies provide evidence for a fifth func-
tional ligand for CCR1. CCR1 is expressed in neutrophils,
monocytes, eosinophils, and lymphocytes, and plays im-
portant roles in pancreatitis (20) and hematopoiesis (21).
CCR1 ligands that contribute to the pathophysiology of
these states are not well defined. HCC-1 can now be added
to the list of chemokines that may have functions in spe-
cific disease processes associated with CCR1 activation.
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Figure 7. Cross-desensitization of cells to HCC-1 and MIP-1a/
RANTES. (A–D) Human monocytes were loaded with Indo-1AM, and
intracellular calcium levels were determined as described in Fig. 2.
Chemokines (100 nM) were added at the indicated time points. HCC-1
was at 1 mM. Shown is one of three similar experiments. (E and F) HEK-
293 cells stably expressing CCR1 were exposed to the indicated chemo-
kines (100 nM), and calcium levels were measured as described above.
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